Gülhan Özçelik Köker
Gülhan Özçelik Köker has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ayhan Hilmi Çekin
Antalya Eğitim ve Araştırma Hastanesi, Gastroenteroloji Kliniği, Antalya
2 shared publications - Feyzi Bostan
Sağlık Bilimleri Üniversitesi Antalya Eğitim ve Araştırma Hastanesi İç Hastalıkları Kliniği, Antalya
2 shared publications - Gokhan Koker
Department of Internal Medicine, University of Health Sciences, Antalya Training and Research Hospital, Antalya, Turkey
2 shared publications - Seyit Uyar
Department of Internal Medicine, University of Health Sciences, Antalya Training & Research Hospital, Antalya 07058, Türkiye
2 shared publications - Yasin Şahintürk
Department of Internal Medicine, Antalya Education Research Hospital, 07080 Antalya, Türkiye
2 shared publications - Ayşe Tan Doğruel
AKDENİZ ÜNİVERSİTESİ, TIP FAKÜLTESİ
1 shared publication
Latest Publications
- Open Access
- 15 August 2026
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 7 (4) , 883-889
Clinicopathological characteristics, immunohistochemistry-based surrogate subtypes and survival in male breast cancer
Aims: Male breast cancer (MBC) is a rare disease, and treatment approaches are largely extrapolated from female breast cancer. This study aims to evaluate clinicopathological features, immunohistochemistry-based surrogate subtypes, treatment approaches, and survival outcomes in MBC patients from Turkiye, where data on this rare disease remain limited. Methods: Forty-seven MBC patients diagnosed between 2005-2024 were retrospectively analyzed. Demographic characteristics, tumor features, immunohistochemistry-based surrogate subtypes, treatment modalities, and survival data were evaluated. Survival analyses were performed using the Kaplan-Meier method, and group comparisons were conducted using the log-rank test. Exploratory associations with overall survival (OS) were evaluated using univariate Cox regression analysis. Analyses used available cases without imputation. Surrogate subtypes were derived from ER, PR, HER2 and Ki-67; HR-positive/HER2negative tumours without Ki-67 were not assigned to luminal A-like or luminal B-like/HER2-negative categories. Results: The median age was 58.4 years (range 31–90), and the median follow-up was 54.9 months (range 2.8–197.3). Stage II was the most common presentation (59.5%), and stage III–IV disease was present in 28.6%. ER/PR/HER2 data were available for 44 patients. Complete five-category immunohistochemistry-based surrogate subtype classification was possible in 35 patients: luminal A-like 31.4% (11/35), luminal B-like/HER2-negative 42.9% (15/35), luminal B-like/HER2-positive 17.1% (6/35), HER2 positive/non-luminal 5.7% (2/35), and triple-negative 2.9% (1/35). Nine additional HR-positive/HER2-negative tumours could not be divided into the two HER2-negative luminal categories because Ki-67 was unavailable. ER positivity was 93.2%, PR positivity 86.4%, and HER2 positivity 18.2%. OS was evaluable in 46 patients; the median OS was 194.3 months and the median disease-free survival was 155.8 months. In exploratory univariate Cox analysis, older age (per 10-year increase: HR 1.76, 95% CI 1.03–2.98, p=0.037), grade 3 histology (HR 3.35, 95% CI 1.17–9.59, p=0.024) and a high Ki-67 index (≥20% vs
- 15 August 2026
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 7 (4) , 883-889
Open AccessClinicopathological characteristics, immunohistochemistry-based surrogate subtypes and survival in male breast cancer
Aims: Male breast cancer (MBC) is a rare disease, and treatment approaches are largely extrapolated from female breast cancer. This study aims to evaluate clinicopathological features, immunohistochemistry-based surrogate subtypes, treatment approaches, and survival outcomes in MBC patients from Turkiye, where data on this rare disease remain limited. Methods: Forty-seven MBC patients diagnosed between 2005-2024 were retrospectively analyzed. Demographic characteristics, tumor features, immunohistochemistry-based surrogate subtypes, treatment modalities, and survival data were evaluated. Survival analyses were performed using the Kaplan-Meier method, and group comparisons were conducted using the log-rank test. Exploratory associations with overall survival (OS) were evaluated using univariate Cox regression analysis. Analyses used available cases without imputation. Surrogate subtypes were derived from ER, PR, HER2 and Ki-67; HR-positive/HER2negative tumours without Ki-67 were not assigned to luminal A-like or luminal B-like/HER2-negative categories. Results: The median age was 58.4 years (range 31–90), and the median follow-up was 54.9 months (range 2.8–197.3). Stage II was the most common presentation (59.5%), and stage III–IV disease was present in 28.6%. ER/PR/HER2 data were available for 44 patients. Complete five-category immunohistochemistry-based surrogate subtype classification was possible in 35 patients: luminal A-like 31.4% (11/35), luminal B-like/HER2-negative 42.9% (15/35), luminal B-like/HER2-positive 17.1% (6/35), HER2 positive/non-luminal 5.7% (2/35), and triple-negative 2.9% (1/35). Nine additional HR-positive/HER2-negative tumours could not be divided into the two HER2-negative luminal categories because Ki-67 was unavailable. ER positivity was 93.2%, PR positivity 86.4%, and HER2 positivity 18.2%. OS was evaluable in 46 patients; the median OS was 194.3 months and the median disease-free survival was 155.8 months. In exploratory univariate Cox analysis, older age (per 10-year increase: HR 1.76, 95% CI 1.03–2.98, p=0.037), grade 3 histology (HR 3.35, 95% CI 1.17–9.59, p=0.024) and a high Ki-67 index (≥20% vs
- 3 September 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (11) , 2409-2410
RE: Drinking pattern and time lag of alcohol consumption with colorectal cancer risk in US men and women
- 3 September 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (11) , 2409-2410
RE: Drinking pattern and time lag of alcohol consumption with colorectal cancer risk in US men and women
- Open Access
- 15 November 2022
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 33 (11) , 925-933
Metformin with Versus without Concomitant Probiotic Therapy in Newly Diagnosed Patients with Type 2 Diabetes or Prediabetes: A Comparative Analysis in Relation to Glycemic Control, Gastrointestinal Side Effects, and Treatment Compliance
Background: To evaluate the impact of concomitant use of probiotic BB-12 in metformin-treated patients with type 2 diabetes or prediabetes on glycemic control, metformin-related gastrointestinal side effects, and treatment compliance. Methods: A total of 156 patients (mean [standard deviation] age: 50.9 [9.9 years], 74.4% females) with newly diagnosed type 2 diabetes or prediabetes were randomly assigned to receive either metformin alone (n = 84, MET group) or metformin plus Bifidobacterium animalis subsp. lactis (BB-12) probiotic (n = 72, MET-PRO group). Data on body mass index (kg/m2), fasting blood glucose (mg/dL), blood lipids, and glycated hemoglobin (HbA1c) levels were recorded at baseline and at the third month of therapy. Data on gastrointestinal intolerance symptoms and treatment noncompliance were also recorded during post-treatment week 1 to week 4. Results: MET-PRO versus MET therapy was associated with a significantly higher rate of treatment compliance (91.7% vs 71.4%, P = .001), greater reduction from baseline HbA1c values (0.9 [0.4-1.6] vs 0.4 [0-1.6] %, P < .001) and lower likelihood of gastrointestinal intolerance symptoms, including abdominal pain (P = .031 to <.001), diarrhea (P = .005 to <.001) and bloating (P = .010 to <.001). Noncompliance developed later (at least 15 days after the therapy) in a significantly higher percentage of patients in the MET group (P = .001 for 15–21 days and P = .002 for 22–28 days). Conclusion: In conclusion, the present study proposes the benefit of combining probiotics with metformin in the treatment of patients with T2D or prediabetes in terms of improved glycemic control and treatment adherence rather than correction of dyslipidemia or weight reduction. Cite this article as: Şahin K, Şahintürk Y, Köker G, et al. Metformin with versus without concomitant probiotic therapy in newly diagnosed patients with type 2 diabetes or prediabetes: A comparative analysis in relation to glycemic control, gastrointestinal side effects, and treatment compliance. Turk J Gastroenterol. 2022;33(11):925-933.
- 15 November 2022
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 33 (11) , 925-933
Open AccessMetformin with Versus without Concomitant Probiotic Therapy in Newly Diagnosed Patients with Type 2 Diabetes or Prediabetes: A Comparative Analysis in Relation to Glycemic Control, Gastrointestinal Side Effects, and Treatment Compliance
Background: To evaluate the impact of concomitant use of probiotic BB-12 in metformin-treated patients with type 2 diabetes or prediabetes on glycemic control, metformin-related gastrointestinal side effects, and treatment compliance. Methods: A total of 156 patients (mean [standard deviation] age: 50.9 [9.9 years], 74.4% females) with newly diagnosed type 2 diabetes or prediabetes were randomly assigned to receive either metformin alone (n = 84, MET group) or metformin plus Bifidobacterium animalis subsp. lactis (BB-12) probiotic (n = 72, MET-PRO group). Data on body mass index (kg/m2), fasting blood glucose (mg/dL), blood lipids, and glycated hemoglobin (HbA1c) levels were recorded at baseline and at the third month of therapy. Data on gastrointestinal intolerance symptoms and treatment noncompliance were also recorded during post-treatment week 1 to week 4. Results: MET-PRO versus MET therapy was associated with a significantly higher rate of treatment compliance (91.7% vs 71.4%, P = .001), greater reduction from baseline HbA1c values (0.9 [0.4-1.6] vs 0.4 [0-1.6] %, P < .001) and lower likelihood of gastrointestinal intolerance symptoms, including abdominal pain (P = .031 to <.001), diarrhea (P = .005 to <.001) and bloating (P = .010 to <.001). Noncompliance developed later (at least 15 days after the therapy) in a significantly higher percentage of patients in the MET group (P = .001 for 15–21 days and P = .002 for 22–28 days). Conclusion: In conclusion, the present study proposes the benefit of combining probiotics with metformin in the treatment of patients with T2D or prediabetes in terms of improved glycemic control and treatment adherence rather than correction of dyslipidemia or weight reduction. Cite this article as: Şahin K, Şahintürk Y, Köker G, et al. Metformin with versus without concomitant probiotic therapy in newly diagnosed patients with type 2 diabetes or prediabetes: A comparative analysis in relation to glycemic control, gastrointestinal side effects, and treatment compliance. Turk J Gastroenterol. 2022;33(11):925-933.
- 26 August 2021
- Published by Turkish Journal of Academic Gastroenterology in Akademik Gastroenteroloji Dergisi
- Vol. 20 (2) , 94-103
Geriatrik popülasyonda kolestatik karaciğer hastalıklarında etiyoloji ve tanısal yaklaşım: 185 vakalık tek merkez deneyimi
Giriş ve Amaç: Kolestaz etiyolojik nedenlerinin ve klinik bulgularının 65 yaş üstü hastalarda geniş hasta popülasyonu ile dökümante edilmesi amaçlandı. Gereç ve Yöntem: Kolestaz nedeniyle yatışı yapılan 65 yaş ve üstü hastalar retrospektif olarak şikayetleri, laboratuvar parametreleri ve görüntüleme sonuçlarına göre değerlendirildi. Benign ve malign etiyolojik nedenler olarak iki gruba ayrılan hastalarda malignite göstergesi olabilecek parametreler için ileri analiz yapıldı. Bulgular: Çalışmamıza retrospektif olarak 65 yaş ve üstü 185 hasta dahil edildi. 109 (%58.9) hastanın etiyolojisi benign, 69 (%37.3) hastanın malign nedenlere bağlı olarak saptandı. 56 hastada (%30.3) koledokolitiazis, 25 hastada (%13.5) kolanjioselüler karsinom, 23 hastada (%12.4) pankreas kanseri en sık görülen tanılardı. En sık başvuru şikayeti karın ağrısıydı. Sarılık şikayetiyle başvuran hastaların %45.6’sı (n: 52) benign, %54.4’ü (n: 62) malign iken kilo kaybıyla başvuran hastaların %6.2’si benign, %93.8’i maligndi. Sarılık ve/veya kilo kaybı şikayetiyle başvuran hastaların malign olma ihtimali istatistiksel olarak anlamlı düzeyde yüksek saptandı (p < 0.001). Çok değişkenli analiz sonuçlarına göre total bilirübin ve alkalen fosfatazın diğer değişkenlerden bağımsız olarak malignite ile pozitif olarak ilişkili olduğu görüldü. Ultrasonografi ile 185 hastanın 85’ine (%46) tanı koyulabilirken, 100’üne (%54) ise tanı koyulamadığı görülmüştür. Sonuç: Geriatrik popülasyonda kolestaz etiyolojisinde benign sebepler daha sık görülmüştür. Sarılık ve kilo kaybı şikayetleri olan ve/veya bilirübin ve alkalen fosfataz düzeyi yüksek olan hastalarda ise malign hastalıklar ayırıcı tanıda öncelikli olmalıdır. Ultrasonografi geriatrik popülasyondaki kolestazlı hastalarda tanı koymada yetersiz bulunmuş, ileri görüntüleme tetkiklerine ihtiyaç duyulmuştur.
- 26 August 2021
- Published by Turkish Journal of Academic Gastroenterology in Akademik Gastroenteroloji Dergisi
- Vol. 20 (2) , 94-103
Geriatrik popülasyonda kolestatik karaciğer hastalıklarında etiyoloji ve tanısal yaklaşım: 185 vakalık tek merkez deneyimi
Giriş ve Amaç: Kolestaz etiyolojik nedenlerinin ve klinik bulgularının 65 yaş üstü hastalarda geniş hasta popülasyonu ile dökümante edilmesi amaçlandı. Gereç ve Yöntem: Kolestaz nedeniyle yatışı yapılan 65 yaş ve üstü hastalar retrospektif olarak şikayetleri, laboratuvar parametreleri ve görüntüleme sonuçlarına göre değerlendirildi. Benign ve malign etiyolojik nedenler olarak iki gruba ayrılan hastalarda malignite göstergesi olabilecek parametreler için ileri analiz yapıldı. Bulgular: Çalışmamıza retrospektif olarak 65 yaş ve üstü 185 hasta dahil edildi. 109 (%58.9) hastanın etiyolojisi benign, 69 (%37.3) hastanın malign nedenlere bağlı olarak saptandı. 56 hastada (%30.3) koledokolitiazis, 25 hastada (%13.5) kolanjioselüler karsinom, 23 hastada (%12.4) pankreas kanseri en sık görülen tanılardı. En sık başvuru şikayeti karın ağrısıydı. Sarılık şikayetiyle başvuran hastaların %45.6’sı (n: 52) benign, %54.4’ü (n: 62) malign iken kilo kaybıyla başvuran hastaların %6.2’si benign, %93.8’i maligndi. Sarılık ve/veya kilo kaybı şikayetiyle başvuran hastaların malign olma ihtimali istatistiksel olarak anlamlı düzeyde yüksek saptandı (p < 0.001). Çok değişkenli analiz sonuçlarına göre total bilirübin ve alkalen fosfatazın diğer değişkenlerden bağımsız olarak malignite ile pozitif olarak ilişkili olduğu görüldü. Ultrasonografi ile 185 hastanın 85’ine (%46) tanı koyulabilirken, 100’üne (%54) ise tanı koyulamadığı görülmüştür. Sonuç: Geriatrik popülasyonda kolestaz etiyolojisinde benign sebepler daha sık görülmüştür. Sarılık ve kilo kaybı şikayetleri olan ve/veya bilirübin ve alkalen fosfataz düzeyi yüksek olan hastalarda ise malign hastalıklar ayırıcı tanıda öncelikli olmalıdır. Ultrasonografi geriatrik popülasyondaki kolestazlı hastalarda tanı koymada yetersiz bulunmuş, ileri görüntüleme tetkiklerine ihtiyaç duyulmuştur.